MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study.

Authors:
Pagani C; Rusconi C; Dalla Pria A; Ravano E; Schommers P and 19 more

Journal:
Blood Adv

Publication Year: 2024

DOI:
10.1182/bloodadvances.2023010704

PMCID:
PMC10877133

PMID:
38207206

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Blood Adv

Abbreviation: Blood Adv

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody tre…
Wang L; Leach V; Muthusamy N and 2 more (2024) - Transparency Score: 3/6
A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell …
Shree T; Haebe S; Czerwinski DK and 15 more (2024) - Transparency Score: 5/6
A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA…
Abou-Ismail MY; Zhang C; Presson AP and 28 more (2024) - Transparency Score: 3/6
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.
Banerjee R; Poh C; Hirayama AV and 9 more (2024) - Transparency Score: 3/6
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymp…
Short NJ; Jabbour E; Jain N and 20 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict-of-interest disclosure: M.S. reports honoraria from Gilead, Servier, Novartis, Incyte, BeiGene, and Istituto Gentili; and research funding from Menarini. L.A. reports consultancy fees from or advisory role in Roche, Janssen-Cilag, Verastem, Incyte, EUSA Pharma, Celgene/Bristol Myers Squibb, Kite/Gilead, and ADC Therapeutics; speakers’ bureau fees from EUSA Pharma and Novartis; and research funding from Gilead Sciences. D.D. reports travel grants from Roche, Gentili, Lilly, and Eisai; and other remuneration from Gentili and Daikii Sanchio. The remaining authors declare no competing financial interests."

Evidence found in paper:

"P.S. is supported by the DFG-Emmy Noether Program (project number 495793173)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025